‘Bristol-Myers Squibb is focused on developing innovative treatment options for patients with severe illnesses like HCV,’ stated Brian Daniels, senior vice president, Development. ‘We are pleased to work with Tibotec to advance the scientific understanding for the prospect of an all-oral program of immediate acting antivirals, which would be a significant advancement for sufferers with HCV. That is a continuation of our leadership in forging partnerships to progress combination antiviral therapy.’.. Bristol-Myers Squibb, Tibotec partner for TMC435 Phase II combination research in HCV Medivir Stomach , the research-based speciality pharmaceutical firm focused on the development of high-value treatments for infectious illnesses, announces that its advancement partner, Tibotec Pharmaceuticals, has entered into an agreement with Bristol-Myers Squibb Company .These medicines are not expected to present a big improvement for patients yet – – they are at the beginning of research in individual trials. Solanezumab failed to help patients with mild to moderate Alzheimer’s within an earlier trial, but researchers are hopeful it shall prove more effective in people at the earliest stages. Many competing research groupings will work on developing other possible therapies: research labs like Petsko’s at Weill Cornell Medical University along with pharmaceutical companies, including a business researching viral therapy that Petsko is usually on the advisory board, Neurophage.